All News

Regardless of whether it is given adjuvantly or as salvage therapy, radiation therapy reduces the likelihood of prostate cancer recurrence, according to a study in the International Journal of Radiation Oncology, Biology, Physics (2004; 59: 329-40).

Trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.

Men who have a low PSA level according to standard PSA testing can still have prostate cancer, according to a recent study in the New England Journal of Medicine (2004; 350:2239-46).

NMP22 test plus cytology may hold potential for tailoring cystoscopic follow-up

San Francisco-Some herbal supplements marketed for erectile dysfunction are not nearly as "safe and effective" as they are touted to be, say concerned experts.

‘TAP’ is used when curvature is

San Francisco--Second-look nephroscopy following percutaneous nephrolithotomy (PNL) could be supplanted by metabolic evaluation and aggressive medical therapy, said researchers from the Duke University Medical Center. Second-look nephroscopy is currently the gold standard for assessing and achieving stone-free status, but the Duke researchers sought to determine whether this additional procedure was necessary.

Lithotripsy is generally excluded, but watch for indirect financial relationships

Studies of the effect of chemotherapy in men with metastatic prostatecancer have been enticing and, at the same time, disappointing. While showingPSA response in some cases, these studies have previously failed to demonstrateimproved survival. This is all about to change, and for the better. We areentering an exciting new era in the management of this patient population.

Here's how to code when LHRH injection, cystoscopy, and biopsy are providedon the same day

San Francisco--Continuing a trend of mixed results seen in previousstudies, neoadjuvant chemotherapy with docetaxel (Taxotere) resulted ina significant PSA response but failed to induce any histologic changes inlocally advanced prostate cancer, Cleveland Clinic investigators reportedat the AUA annual meeting.

Oceanside, NY--In men with clinically localized prostate cancer,monotherapy with radical prostatectomy, external beam radiation therapy,or permanent prostate brachytherapy offer the same excellent chance of biochemicalsuccess, according to the results of a large, retrospective study.

San Francisco--Still known primarily for its ability to smoothfacial wrinkles, botulinum toxin A (Botox) is gaining acceptance as a treatmentoption for refractory overactive and neurogenic bladder.

Vanilloid is shown to improve urgency but not pain, leakage, nocturia, or enuresis

FDA will hold a public workshop on prostate cancer as part of its ongoing series of meetings on oncology clinical trial endpoints.

The FDA has established donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable diseases during transplantation.

The Society of Urologic Nurses and Associates (SUNA) released two position statements-one on bladder cancer and the other on the nursing shortage.

The latest update of AUA guidelines for management of organic erectile dysfunction will focus on novel treatment recommendations and suggestions for study designs that minimize conflicts of interest in post-marketing comparisons of oral drug therapies.

Patrick C. Walsh, MD, will step down in July as director of the Brady Urological Institute at Johns Hopkins, a position he has held since 1974.

Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.

Results from an ex vivo study demonstrating effects of the nonselective alpha-1 receptor antagonist doxazosin (Cardura) on ureteral contractility raises questions about the role of alpha-blocker treatment in the management of ureteral stone disease, say urologists from the University of Wisconsin.

Gynecare, a division of Ethicon, Inc., offers the Gynecare Monitorr urodynamicmeasurement system, featuring a new type of urethral pressure measurementfor stress incontinence-urethral retro-resistance pressure.

Total attendance at this year's AUA annual meeting in San Francisco increasedby about 1,500 over last year's meeting in Chicago, according to unauditedstatistics released on Monday. As of Monday, total professional attendanceat the meeting was 11,538, compared with 10,031 at the 2003 meeting.

American Medical Systems announced Monday that its Apogee System forvaginal vault prolapse repair received FDA clearance. The company said itwill begin physician training in preparation for commercial release laterthis year.

The Coalition for the Advancement of Prosthetic Urology has taken a significantstep in what is likely to be a long march toward securing equitable paymentfor urologic prostheses, said John Mulcahy, MD, chairman of CAPU's boardof directors, during a briefing held during the AUA annual meeting Tuesday.

A large, international, multicenter study has shattered one common assumptionabout renal cell carcinoma. The overall prognosis for chromophobe carcinomasis better than for clear-cell or papillary tumors, rather than the opposite.However, all three tumor types have equivalent survival when adjusted forstage and grade.

The use of a dynamic contrast (gadolinium)-enhanced T2-weighted MRI (DCE-MRI)appears to be a very promising new means of detecting prostate cancer lesions,according to a National Cancer Institute-funded study.

Pregnancy rates after varicocelectomy negatively correlate to the lengthof time the patient was infertile, according to long-term research fromthe University of Istanbul, Turkey.